Trelegy Ellipta is for adult patients with moderate/severe COPD on treatment with an ICS/LABA or LAMA/LABA who are symptomatic and at risk of an exacerbation14

Managing the frail COPD patient

ERS 2021 virtual congress GSK symposium for COPD. Experts Neil Barnes and Raj Sharma discuss the issues and management of frail COPD patients.

Trelegy consists of an ICS, a LABA, and a LAMA. delivered in the Ellipta inhaler14

Ellipta open inhaler close
  • Slide the cover down until you hear a ‘click’.
  • While holding the inhaler away from your mouth, breathe out as far as comfortable
Ellipta open inhaler close
  • Put the mouthpiece between your lips, and close your lips firmly around it.
  • Take one long, steady, deep breath in and hold this breath for at least 3-4 seconds
Ellipta open inhaler close
  • Remove the inhaler from your mouth and breathe out slowly and gently.
  • Slide the cover upwards as far as it will go to cover the mouthpiece.

Dont settle for an MDI, when you can give the preferred, easy-to-use Ellipta device8

Significantly fewer COPD patients made a critical error* with the Ellipta inhaler compared with other commonly used COPD inhalers after reading the patient information leaflet (p<0.001).8

With Ellipta:

5.5x fewer patients made a critical error vs. Turbohaler**
4.8x fewer patients made a critical error vs. MDI**

*Critical errors defined as errors that are likely to result in no, or minimal, medication being delivered to the lung

Open label single visit, placebo inhaler, crossover comparison in patients naïve to Ellipta and the comparator inhalers.
Critical errors: Ellipta vs. Turbohaler (n=100) 8% vs. 44%; Ellipta vs. MDI (n=80) 13% (10/80) vs. 60% (48/80)8

Get started with Trelegy Ellipta

Prescribing Information Links

Trelegy Ellipta Prescribing Information (pdf)
Relvar Ellipta Prescribing Information (pdf)
Anoro Ellipta Prescribing Information (pdf)
Incruse Ellipta Prescribing Information (pdf)

Trelegy Ellipta OD is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist.14


DPI, dry powder inhaler; FEV1, forced expiratory volume in one second; FF, fluticasone furoate; FOR, formoterol; HRQoL, health-related quality of life; ICS, inhaled corticosteroid; ITT, intent-to-treat; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; OD, once daily; QoL, quality of life; pMDI, pressurised metered dose inhaler; UMEC, umeclidinium; VI, vilanterol


  1. IQVIA MIDAS data, volume (units) since launch up to (and including) November 2021
  2. GSK 50 years of innovation REF-36689
  3. Vestbo J et al N Engl J Med 2016; 375:1253-60
  4. Maltais F et al Adv Ther 2019; 36:2434-2449
  5. Feldman G Adv Ther 2017 34:2518-2533
  6. Feldman GJ et al Int J Chron Obstruct Pulmon Dis 2016: 11:719-730
  7. Certification of carbon neutrality for Trelegy Ellipta
  8. van der Palen J. et al NPJ P rim Care Respir Med 2016 26:16079
  9. Analysis by GSK based on IQVIA DRx, COPD Triple Therapy data set. Patients November 2021. REF-146731
  10. Department of health - An Outcomes Strategy for Chronic Obstructive Pulmonary Disease (COPD) and Asthma in England
  11. LPD, IQVIA Ltd, incorporating data derived from THIN, A Cegedim Database, Nov 2021
  12. British Thoracic Society (BTS) 2020 Position Statement: Environment and Lung Health
  13. The NHS Long Term Plan 2019
  14. Trelegy Ellipta SmPC

Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

August 2022 | PM-GB-FVU-WCNT-200014 (V5.0)